ZetaPrime

ZetaPrime is an investigational, locoregionally administered neoadjuvant therapy from Zetagen for **primary hormone receptor-positive breast cancer**. The candidate uses a proprietary hydrogel-like lipid carrier designed for controlled release of two small molecules following a single intratumoral injection; public disclosures describe one component as a novel molecular entity and indicate compatibility with CDK4 or CDK4/6 inhibitors. Its specific molecular targets and the identities of its fixed active ingredients have not been publicly disclosed. ZetaPrime remained in preclinical development, with planned GMP manufacturing, in the latest identified company disclosures. ([zetagen.com](https://zetagen.com/press-release/zetagen-secures-composition-of-matter-patents-from-uspto/))

Other names

ZetaPrime